VANCOUVER, BC, July 7, 2021 /CNW/ – MYND Life Sciences Inc.(CSE: MYND) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches, pharmaceuticals and vaccines, is pleased to provide a corporate update on its operations and progress on its strategic initiatives to the end of Q2 2021. “A key difference between MYND and other psychedelic…


Previous articleClerkenwell Signs First Multi-million Pound Contract with International Psychedelic Bio-tech Company
Next articleMindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014